Scanning, scanning & scanning ...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Halozyme Therapeutics beats by $0.03, beats on revenue
Halozyme Therapeutics (NASDAQ:HALO): Q4 EPS of -$0.04 beats by $0.03.
Revenue of $30.4M (+143.2% Y/Y) beats by $4.81M.
Shares +4.8%.
Halozyme Therapeutics beats by $0.03, beats on revenue
Halozyme Therapeutics (NASDAQ:HALO): Q4 EPS of -$0.04 beats by $0.03.
Revenue of $30.4M (+143.2% Y/Y) beats by $4.81M.
Shares +4.8%.
Everyday Health beats by $0.02, revenue in-line
Everyday Health (NYSE:EVDY): Q4 EPS of $0.41 beats by $0.02.
Revenue of $63.04M (+18.7% Y/Y) in-line.
RigNet misses by $0.24, misses on revenue
RigNet (NASDAQ:RNET): Q4 EPS of $0.11 misses by $0.24.
Revenue of $86.65M (+45.1% Y/Y) misses by $1.51M.
NorthStar Realty down 1.9% on secondary offering
The total size of the offering is 60M shares, of which 40M are subject to a forward sale agreement with Deutsche Bank. The underwriter greenshoe is for another 9M shares.
Proceeds will be used to help fund the $1.3B purchase of a European office portfolio, pay down some debt, and for firepower for additional acquisitions.
Source: Press Release
NRF -1.9% after hours.
NorthStar Realty down 1.9% on secondary offering
The total size of the offering is 60M shares, of which 40M are subject to a forward sale agreement with Deutsche Bank. The underwriter greenshoe is for another 9M shares.
Proceeds will be used to help fund the $1.3B purchase of a European office portfolio, pay down some debt, and for firepower for additional acquisitions.
Source: Press Release
NRF -1.9% after hours.
Altisource Portfolio misses by $0.28, beats on revenue
Altisource Portfolio (NASDAQ:ASPS): Q4 EPS of $0.30 misses by $0.28.
Revenue of $255.88M (+15.0% Y/Y) beats by $13.61M.
Altisource Portfolio misses by $0.28, beats on revenue
Altisource Portfolio (NASDAQ:ASPS): Q4 EPS of $0.30 misses by $0.28.
Revenue of $255.88M (+15.0% Y/Y) beats by $13.61M.
Alexander & Baldwin beats on revenue
Alexander & Baldwin (NYSE:ALEX): Q4 Operating profit before discontinued operations of $26.5M.
Revenue of $165.1M (-19.4% Y/Y) beats by $22.56M.
EPIQ Systems beats by $0.04, misses on revenue
EPIQ Systems (NASDAQ:EPIQ): Q4 EPS of $0.22 beats by $0.04.
Revenue of $108.5M (-10.3% Y/Y) misses by $4.52M.
Matador Resources EPS of $0.63
Matador Resources (NYSE:MTDR): Q4 EPS of $0.63 may not be comparable to consensus of $0.19.
Revenue of $93.1M (+33.6% Y/Y) misses by $7.35M.
OPOWER beats by $0.03, beats on revenue
OPOWER (NYSE:OPWR): Q4 EPS of -$0.14 beats by $0.03.
Revenue of $34.85M (+34.2% Y/Y) beats by $1.4M.
Oaktree launches 4M share secondary
Oaktree Capital (NYSE:OAK) won't keep any of the proceeds, but instead use the money to buy back interests in its businesses from certain board members and current and former management.
Source: Press Release
Shares -1.5% after hours.
Mylan EPS in-line, beats on revenue
Mylan (NASDAQ:MYL): Q4 EPS of $1.05 in-line.
Revenue of $2.08B (+14.9% Y/Y) beats by $10M.
MBIA EPS of $0.10
MBIA (NYSE:MBI): Q4 EPS of $0.10 may not be comparable to consensus of $0.02.
Revenue of $104M (-4.6% Y/Y) beats by $24.1M.
Intrexon beats by $0.10, beats on revenue
Intrexon (NYSE:XON): Q4 EPS of -$0.06 beats by $0.10.
Revenue of $31.1M (+335.6% Y/Y) beats by $4.99M.
Guidewire Software beats by $0.06, beats on revenue
Guidewire Software (NYSE:GWRE): FQ2 EPS of $0.17 beats by $0.06.
Revenue of $89.44M (+7.1% Y/Y) beats by $3.22M.
DXP Enterprises misses by $0.13, beats on revenue
DXP Enterprises (NASDAQ:DXPE): Q4 EPS of $0.95 misses by $0.13.
Revenue of $382.5M (+21.9% Y/Y) beats by $3.09M.
Chuy's beats by $0.01, beats on revenue
Chuy's (NASDAQ:CHUY): Q4 EPS of $0.14 beats by $0.01.
Revenue of $61.8M (+21.7% Y/Y) beats by $0.13M.
Palo Alto Networks beats by $0.02, beats on revenue
Palo Alto Networks (NYSE:PANW): FQ2 EPS of $0.19 beats by $0.02.
Revenue of $217.65M (+54.3% Y/Y) beats by $13.65M.
Shares +0.58%.
Palo Alto Networks beats by $0.02, beats on revenue
Palo Alto Networks (NYSE:PANW): FQ2 EPS of $0.19 beats by $0.02.
Revenue of $217.65M (+54.3% Y/Y) beats by $13.65M.
Shares +0.58%.
This ... i doubt lol
Portfolio Recovery misses by $0.18, beats on revenue
Portfolio Recovery (NASDAQ:PRAA): Q4 EPS of $0.93 misses by $0.18.
Revenue of $250.7M (+35.6% Y/Y) beats by $3.41M.
Sanchez Energy misses by $0.08, misses on revenue
Sanchez Energy (NYSE:SN): Q4 EPS of -$0.19 misses by $0.08.
Revenue of $172.49M (+32.6% Y/Y) misses by $17.34M.
Ligand up on Kyprolis study
Thinly-traded Ligand Pharmaceuticals (LGND +15.5%) jumps on a 5x surge in volume in response to the positive news on Amgen's (AMGN +1.1%) Kyprolis (carfilzomib) study. Ligand is eligible to receive milestone and royalty payments on sales of Captisol, which carfilzomib's IV formulation utilizes. Ligand and Proteolix entered into a collaboration in 2005 to explore the use to Captisol. Onyx Pharmaceuticals acquired Proteolix in 2009 and Amgen acquired Onyx in 2013.
Captisol is a formulation technology. It is a uniquely modified cyclodextrin, which improves the solubility, stability, bioavailability and dosing of active pharmaceutical ingredients.
Ligand up on Kyprolis study
Thinly-traded Ligand Pharmaceuticals (LGND +15.5%) jumps on a 5x surge in volume in response to the positive news on Amgen's (AMGN +1.1%) Kyprolis (carfilzomib) study. Ligand is eligible to receive milestone and royalty payments on sales of Captisol, which carfilzomib's IV formulation utilizes. Ligand and Proteolix entered into a collaboration in 2005 to explore the use to Captisol. Onyx Pharmaceuticals acquired Proteolix in 2009 and Amgen acquired Onyx in 2013.
Captisol is a formulation technology. It is a uniquely modified cyclodextrin, which improves the solubility, stability, bioavailability and dosing of active pharmaceutical ingredients.
DQ had a very nice day !
Caesars Entertainment EPS of -$6.90
Caesars Entertainment (NASDAQ:CZR): Q4 EPS of -$6.90 may not be comparable to consensus of -$1.65.
Revenue of $2.1B (+5.0% Y/Y) misses by $120M.
Shares -1.2%.
Caesars Entertainment EPS of -$6.90
Caesars Entertainment (NASDAQ:CZR): Q4 EPS of -$6.90 may not be comparable to consensus of -$1.65.
Revenue of $2.1B (+5.0% Y/Y) misses by $120M.
Shares -1.2%.
Rouse Properties FFO in-line, beats on revenue
Rouse Properties (NYSE:RSE): Q4 FFO of $0.46 in-line.
Revenue of $81.71M (+21.3% Y/Y) beats by $23.35M.
Arena Pharmaceuticals misses by $0.03, misses on revenue
Arena Pharmaceuticals (NASDAQ:ARNA): Q4 EPS of -$0.15 misses by $0.03.
Revenue of $9.2M (+41.1% Y/Y) misses by $1.16M.
CNinsure beats by $0.04
CNinsure (NASDAQ:CISG): Q4 EPS of $0.09 beats by $0.04.
Revenue of $102M (+25.6% Y/Y)
At the close ...
NASDAQ 5008.1 44.57 0.9%
DJIA 18286.44 153.74 0.85%
S&P 2117.25 12.75 0.61%
> BPZ Energy to be de-listed from NYSE
The NYSE says it is suspending trading in BPZ Energy (BPZ -36%) and will begin delisting proceedings, as the share price is "abnormally low" and no longer suitable for a listing on the exchange.
BPZ earlier said it is exercising a 10-day grace period for repaying the $62M in principal and interest owed on its convertible bonds, and that it is in talks with some of the bondholders about a potential restructuring of the debt.
WBAI 10.05 +0.82 (8.88%)
WBAI 9.91 +0.68 (7.37%) < link back
QIHU 47.00 +1.27 (2.78%) still watching < link back
NVGS 18.95 +0.54 (2.93%) < link back